Please login to the form below

Not currently logged in
Email:
Password:

Accretio appoints Neil Levinson as strategy director

He joins the healthcare consultancy from Kaiser Associates

AccretioAccretio, part of the OPEN health group of companies, has appointed Neil Levinson as its strategy director.

Levinson will join the Accretio leadership team alongside managing director Richard Baderin and operations director Charlotte Richards.

Speaking of his new appointment, Levinson said: “Accretio has pioneered novel ways to support life science companies achieve improved results for their brand.

“I look forward to expanding this offering and maximising the breadth of experience from the broader OPEN Health group to provide outcomes-focused consulting and implementation services for global and UK clients.”

Most recently, Levinson was vice president at Kaiser Associates, a global strategy-consulting firm, where he led the European healthcare practice.

Prior to Kaiser, Levinson spent ten years at IMS Health, where he was senior principal, leading the UK and Ireland consulting services business.

Commenting on his appointment, Baderin, said: “Neil’s appointment cements Accretio’s evolution to a fully-fledged strategic solutions and implementation services company led by a team with pharmaceutical, consultancy and agency heritage.

“It’s great to have someone of Neil’s calibre as part of the leadership team as we embark on the next phase of Accretio’s journey.”

24th April 2018

From: Marketing

Share

Tags

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM

AMICULUM is an independent family of 11 branded agencies that deliver communications and consultancy services to pharmaceutical, biotechnology and health...

Latest intelligence

Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...
The problem with clinical trials (and how virtual insight-gathering can help)
While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
The rise of digital healthcare – fuelled by open innovation in healthtech hubs
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...